Bimagrumab

Bimagrumab is an antibody that blocks activin type II receptors (ActRII), the cellular brake pedal on muscle growth. Lilly is testing it as an add-on to tirzepatide in obesity, betting that pairing fat-loss with muscle preservation cracks open a problem GLP-1s created: when patients drop 20% of body weight on Mounjaro or Wegovy, roughly a quarter of what they lose is lean mass - SURMOUNT-1 body composition substudy showed ~75% fat / ~25% lean across age groups on tirzepatide [11]. NCT06643728 is the Phase 2 combination trial reading out body weight and composition data in 2026 [2]. The biology already cleared a Phase 2 with semaglutide that showed selective fat loss with strong total weight reduction, published in Nature Medicine [1, 5]. So the question now is whether the effect holds on top of tirzepatide. Lilly paid up to $1.925B for Versanis to acquire this asset in July 2023 [9], signaling it's a pillar of the post-GLP-1 obesity strategy, not a hedge. The competitive landscape has tightened sharply since: Regeneron's trevogrumab and Scholar Rock's apitegromab have both posted positive Phase 2 lean-preservation data in GLP-1 combos in 2025 [12, 13].

Bimagrumab is investigational for obesity but carries more history than most Phase 2 assets. Novartis originally developed it as BYM338 for inclusion body myositis, a rare muscle-wasting disease, and earned FDA breakthrough designation in 2013. The Phase 2/3 there failed on functional endpoints despite gains in muscle mass [4, 7]. Versanis Bio later licensed the asset, ran the obesity Phase 2 with semaglutide (NCT05616013, n=507) [3], and Lilly acquired Versanis for up to $1.925B in July 2023, closing in August 2023 [9]. The compound is now LY3985863 in Lilly's pipeline [10]. The current Phase 2 (NCT06643728, n=252) is active, not recruiting, meaning dosing is at or near complete and readout should land in 2026 [2]. Sponsor is Lilly. Specific bimagrumab dose levels in the trial have not been disclosed in detail in public registries - the prior Versanis-era Phase 2 used 10 mg/kg IV every 4 weeks as the highest evaluated dose [1]. A Phase 1 PK study of bimagrumab with tirzepatide in healthy volunteers (NCT06890611) has already completed. A separate investigator-initiated Phase 2 at Massachusetts General Hospital (NCT05933499, n=63) is running with DEXA-based body composition endpoints [8]. No FDA designations on file for the obesity indication yet. Lilly has not pushed for breakthrough or fast track, likely waiting on the Phase 2 readout before defining the regulatory path.

Muscle size is set by a tug-of-war. Growth factors push muscle to build. A protein called myostatin holds it back. Myostatin and the related activins bind ActRII (activin type II receptors) on muscle cells and signal them to stop growing. Bimagrumab is an antibody that sits on ActRII (both the 2A and 2B subtypes) and blocks myostatin and activin from binding, lifting that brake [4]. The unexpected finding from obesity trials: blocking this pathway not only preserves muscle but actively drives fat loss. The mechanism is not fully established. The most parsimonious explanation is increased resting metabolic demand from greater lean mass; a brown-adipose-activation hypothesis appears in some preclinical literature but has not been demonstrated in the human Phase 2 data and should be treated as speculative. The published Phase 2 with semaglutide showed bimagrumab plus semaglutide produced substantial total weight loss where most of what came off was fat, while bimagrumab alone increased lean mass even as fat dropped [1]. Mechanism validation is strong on genetics. Humans and animals with myostatin loss-of-function mutations are heavily muscled - Belgian Blue cattle, the well-documented case of a hypermuscular German child. The Phase 2 inclusion body myositis data showed bimagrumab reliably increased muscle mass; the failure there was functional translation, not biology [4]. In obesity, where the endpoint you actually want is body composition rather than walking speed, the biology and the endpoint line up much better. This is a target where the question shifts from 'does blockade do anything' to 'does the readout capture what blockade does.'

NCT06643728 is a Phase 2, n=252, testing bimagrumab alone and in combination with tirzepatide (Lilly's GLP-1/GIP dual agonist) in adults with obesity or overweight [2]. Primary endpoint: percent change in body weight from baseline. The trial is active, not recruiting, with readout expected in 2026. Sponsor is Lilly directly. The Versanis-era combo trial (NCT05616013) used bimagrumab 10 mg/kg IV q4w as the top dose [1]; doses in NCT06643728 are not fully detailed in the public registry record. The design choice that matters: Lilly is putting bimagrumab against and on top of tirzepatide, not semaglutide. Tirzepatide alone already delivers ~22.5% weight loss at the highest dose in SURMOUNT-1. The real question is whether adding bimagrumab improves body composition - more fat off, less lean mass off - without sacrificing total weight loss. That's a body composition study disguised as a weight study, and the gap matters for how the readout gets interpreted by regulators and the market [6]. The MGH investigator-initiated Phase 2 (NCT05933499, n=63) complements this with DEXA-based lean mass and bone density as primary endpoints [8]. Bone is an emerging concern. Rapid GLP-1 weight loss has been associated with bone mineral density loss, and ActRII blockade has both muscle and bone implications [6]. If the MGH study shows bimagrumab preserves bone alongside muscle, that materially strengthens the combination thesis. If it shows neutral or worse bone outcomes, that opens a long-term safety question Lilly will have to address.

The model puts this drug's chance of eventual approval at 24%. That number starts from the historical approval rate for Phase 2 drugs in this area - about 35% - then adjusts up or down based on ten specific facts about the trial and its sponsor. Three factors push the estimate up: an unusually large number of trial arms (12), enrollment bigger than typical for this phase, and more secondary endpoints than average; one factor pulls it down, which is weak or limited results from earlier-phase studies. The remaining factors are close to average for this stage, so they have little effect on the final number.

Efficacy risk: the bar is unusually high. Tirzepatide alone delivers 22.5% weight loss. If bimagrumab plus tirzepatide reads out at 24%, that's a marginal weight-loss story unless body composition data is striking. The mechanism could deliver genuine lean mass preservation but underwhelm on the primary endpoint because there's so little headroom left. Safety risk: bimagrumab has known on-target signals from prior trials, including mild diarrhea, pancreatic enzyme elevations, and acne-like skin findings [4]. More concerning, ActRII signaling matters in cardiovascular, bone, and reproductive biology. Long-term blockade in a chronic obesity setting raises questions the shorter IBM and sarcopenia trials didn't have to answer. Bone is the specific worry given GLP-1s already pressure BMD [6]. Notably, the Regeneron COURAGE triplet (semaglutide + trevogrumab + garetosmab) reported two deaths in the triplet arm [12]; while not directly translatable to bimagrumab, it shows that stacking biologics on a GLP-1 in a high-comorbidity population is not free. Execution risk: low. Lilly runs trials well and the active-not-recruiting status is on schedule. Commercial risk: this is the biggest one. Even if the combination shows better body composition, payers already cover obesity drugs grudgingly. Stacking a second injectable biologic on top of tirzepatide will face brutal pricing pressure. Lilly's acquisition rationale explicitly framed bimagrumab as a combination partner for the incretin portfolio [9], which signals the likely commercial path is a co-administered or eventual fixed-dose regimen rather than a standalone add-on. Lilly has not publicly committed to an FDC product yet - that decision likely waits on the Phase 2 readout. Regulatory risk: FDA has not yet formally accepted body composition or lean mass preservation as an approvable obesity endpoint [6]. Lilly may need to argue this through with the agency. IP risk: bimagrumab originated at Novartis circa 2010. Core composition-of-matter patents on biologics filed in that window typically expire in the early 2030s (with potential biosimilar entry shortly after). Secondary patents on formulation, dosing regimen, and method-of-use in obesity could extend effective exclusivity, but for a drug unlikely to reach market before ~2029, Lilly is plausibly buying a partial-decade exclusivity window unless secondary IP holds up. Specific expiry dates were not verifiable from public sources in this revision and warrant a dedicated IP review.

Worth watching, and one of the more interesting Phase 2 readouts of 2026 - but the competitive backdrop has changed. The signal to wait for: the NCT06643728 readout with body composition data, not just total weight. If bimagrumab plus tirzepatide shows >90% of weight loss coming from fat versus ~75% for tirzepatide alone, while matching or exceeding total weight loss, that's the inflection point. Anything short of that and the program becomes a niche play in sarcopenic obesity. Lilly paid up to $1.925B for Versanis to get this asset [9]. They're not running a side bet. This is positioned as a pillar of the post-GLP-1 obesity franchise alongside retatrutide and oral orforglipron [10]. The strategic logic: the next decade of obesity treatment is about quality of weight loss and metabolic outcomes, not just kilos off the scale. Bimagrumab is the body composition lever. The commercial exit path Lilly has signaled - though not formally committed to - is an incretin-plus-ActRII combination product; the acquisition press release [9] explicitly framed bimagrumab as a combination partner for tirzepatide. Competitors to watch (and this is the material change in this revision): - **Regeneron - trevogrumab + garetosmab (anti-myostatin + anti-activin A):** Phase 2 COURAGE 26-week results presented at EASD 2025. Triplet with semaglutide produced 92.6% fat-mass / 7.4% lean-mass split, but with two deaths in the triplet arm raising a safety overhang [12]. Currently ahead of bimagrumab on data. - **Scholar Rock - apitegromab (selective latent myostatin):** Phase 2 EMBRAZE with tirzepatide read out positive on June 18, 2025, showing 54.9% additional lean mass preserved vs tirzepatide alone (p=0.001) at 10 mg/kg [13]. Also ahead of bimagrumab on data, with a cleaner safety profile than the Regeneron triplet. - **Garetosmab (Regeneron, anti-activin A):** Part of the COURAGE combination; standalone obesity development less clear. The asymmetry: both selective competitors hit primary endpoints before Lilly's key-quality Phase 2 readout. Bimagrumab's differentiator is breadth - it blocks both ActRIIA and ActRIIB and shuts down activin and myostatin simultaneously, which may explain why the semaglutide combo Phase 2 produced active fat loss rather than only lean preservation. If NCT06643728 reproduces that pattern on top of tirzepatide, bimagrumab has a distinct profile worth the $1.925B. If it merely matches apitegromab on lean preservation without the active fat-loss signal, the selective competitors arguably win on safety and tolerability. Check back: late 2026 for the NCT06643728 readout, and ongoing for the MGH bone/DEXA data. That readout window is when this becomes either a multi-billion-dollar asset or fades into a specialty indication. Patent runway and any Lilly FDC announcement are the other watchpoints.